CRISPR Therapeutics partnered with big biotech Vertex Pharmaceuticals ( VRTX 3.40%) on Casgevy. Although Vertex takes a ...

Some of the gains have come as the broader market has rallied, but there are signs fundamental factors are at play as well.

Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...

Amid a shaky macroeconomic backdrop, biotech stocks have underperformed, with XBI showing poor technical momentum and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The FDA's decision to appoint Vinay Prasad, MD, MPH, to head its Center for Biologics Evaluation and Research (CBER) raised ...

Good morning. Biotech was not faring well yesterday, after we got the news that Vinay Prasad was chosen to be the next ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had ...

It's been 13 weeks since Aardvark Therapeutics' $94 million initial public offering on Feb. 13 in the bleakest streak for ...

Sana Biotechnology, Inc.’s SANA share price has dipped by 5.61%, which has investors questioning if this is right time to buy ...

Concord Biotech, operating in the Pharmaceuticals sector and classified as a Smallcap on the BSE, currently has its share price at ₹1525. The stock has experienced fluctuations today ...